Lobe SciencesCSE: LOBE

Pre-IND work advancing per FDA guidance; preparing for US clinical trial authorization

Why it matters: FDA Pre-IND marks the transition from international (Jordan Phase 1a) to US regulatory pathway. Success would enable Phase 1b/2 in the US for cluster headache.

Watch next: Pre-IND FDA feedback; US Phase 1b/2 trial design for cluster headache; OUD programme initiation

Actual: Jun 27, 2023

Phase 1 clinical trial initiated in Jordan (NCT06035900): 10 healthy volunteers, open-label, single oral dose PK study of L-130 (Psilocin Mucate)

Why it matters: L-130 is a proprietary stabilized psilocin conjugate with superior bioavailability vs psilocybin (which requires hepatic conversion to psilocin). Direct psilocin delivery provides more predictable pharmacokinetics and potentially faster onset.

Actual: Dec 7, 2023

Phase 1 completed: all subjects dosed with no significant adverse events; Cmax significantly higher than expected

Why it matters: Higher-than-expected peak plasma concentration validates L-130's superior bioavailability hypothesis. No safety signals. Data supports progression to efficacy studies.

Actual: Jun 1, 2024

Phase 1 PK results published in Journal of Clinical Pharmacology and Therapeutics (peer-reviewed)

Why it matters: Peer-reviewed publication provides the definitive Phase 1a data record and supports the Pre-IND submission to FDA.

Actual: Jan 1, 2025

Preclinical paper published in Journal of Psychoactive Drugs: daily administration of L-130 produces favorable safety profile and anxiolytic effects in rodents exposed to chronic stress

Why it matters: Demonstrates daily dosing safety and anxiolytic efficacy in a chronic stress model — relevant for cluster headache patients who experience chronic/episodic pain cycles. L-130 may work both acutely and prophylactically.

Actual: Jun 1, 2025

Cynaptec Pharmaceuticals (64% owned by Lobe Sciences) completed $8.46M financing at $22.56M post-money valuation

Why it matters: Substantial capitalization for the subsidiary running L-130 development. Lobe retains majority control while de-risking via subsidiary structure. R&D spending increased 130x year-over-year, signaling real clinical advancement.

Actual: Sep 9, 2025

Presentation at Clusterbusters 20th Annual U.S. Patient Conference (Grapevine, TX)

Why it matters: Cluster headache patient community engagement. Clusterbusters is the leading cluster headache advocacy organization and the primary patient recruitment channel for cluster headache trials.